Bli medlem
Bli medlem

Du är här

2021-10-26

Idogen publishes interim report for 1 January - 30 September 2021

Idogen AB's interim report for January to September 2021 is available on the company's website https://idogen.com/en/investors/financial-reports/

Third quarter (July-September 2021)

  •   Övriga rörelseintäkter uppgick till 7 171 (1 968) TSEK.
  •   Rörelseresultatet uppgick till -5 249 (-4 779) TSEK.
  •   Periodens resultat uppgick till -5 191 (-4 729) TSEK.
  •   Kassaflödet från den löpande verksamheten uppgick till -9 029 (-6 864) TSEK.
  •   Resultat per aktie före utspädning uppgick till -0,28 (-0,52) SEK. Resultat per aktie efter utspädning uppgick till -0,28 SEK (-0,52).

Period (January-September 2021)

  •   Other operating income amounted to KSEK 10,580 (6,164).
  •   Operating loss was KSEK -25,413 (-18,704).
  •   Loss for the period totalled KSEK -25,326 (-18,925).
  •   Cash flow from operating activities was KSEK -25,116 (-17,653).
  •   Loss per share before dilution was SEK -1.39 (-2.45). Loss per share after dilution was SEK -1.39 (-2.45).

Significant events in the third quarter

  •   Idogen initiated new activities in order to maximize the effect of the tolerogenic cell therapy IDO 8 before the start of the first clinical trial.
  •   Preparations for the submission of a clinical trial application (CTA) for the start of the planned clinical trial on patients with antibodies to their treatment of hemophilia A is expected to be submitted to the relevant authorities by the end of 2021.

Significant events during the period

  •   The COVID-19 pandemic affected work at the Radboud University Medical Center.
  •   Idogen appointed highly reputable scientific advisors in transplantation.
  •   A Corporate Governance section was added to the Annual Report, and Idogen is now compliant with the Nasdaq listing requirements.
  •   An additional payment of MSEK 3 was received from the EU's Horizon 2020 program.
  •   The European Patent Office (EPO) granted a European patent to protect the company's tolerogenic cell therapy.

Significant events after the end of the period

  •   Idogen generated proceeds of MSEK 9.8 after issue costs when shares were subscribed for with the support of subscription warrants (TO 4).
  •   No other significant events occurred after the end of the period that affected the results or financial position.

For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 (0)70 918 00 10
Email: anders.karlsson@idogen.com

Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm
Phone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se

The information was submitted for publication, through the agency of the contact persons set out above, on 26 October, 2021 08:47 CEST.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com

Författare Cision